CHMP recommends extension of approval for Adcetris plus CHP in anaplastic large cell lymphoma.- Takeda Pharma
Related news and insights
Roche announced European Medicines Agency (EMA) approval of a new, shorter 90-minute Gazyvaro (obinutuzumab) infusion time, administered in combination with chemotherapy in patients with previously treated or untreated advanced follicular lymphoma (FL).
BeiGene announced that Brukinsa (zanubrutinib) has been approved in Australia for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
BeiGene, Ltd. announced that Brukinsa (zanubrutinib) has received accelerated approval from the FDA for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.This accelerated approval is based on overall response rate (ORR).